Stock Track | Moderna Soars 5% Intraday on Bird Flu Vaccine Funding and Regulatory Updates

Stock Track01:00

Moderna, Inc. (MRNA) saw its stock soar by 5% during intraday trading on Monday, continuing its recent outperformance streak. The biotech company has been gaining momentum following several positive developments.

Last week, Moderna announced it would receive up to $54.3 million in funding from a global coalition to support the late-stage development of its experimental bird flu vaccine. Additionally, the company secured a five-year loan facility for up to $1.5 billion in November, targeting up to 10% revenue growth next year. These financial boosts have bolstered investor confidence.

Further supporting the stock, the U.S. Food and Drug Administration (FDA) confirmed it has no plans to impose a "black box" warning on COVID-19 vaccines, easing concerns about potential regulatory hurdles. Despite recent gains, Moderna's stock remains down ~15% year-to-date, reflecting ongoing investor caution.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment